The Benefits of Novel PSA Velocity Risk Count Testing For Prostate Cancer

The Benefits of Novel PSA Velocity Risk Count Testing For Prostate Cancer

A new study by NYU Langone Medical Center and Northwestern University Feinberg School of Medicine shows novel PSA velocity (PSAV) risk count testing may provide a more effective way for physicians to screen men for clinically significant prostate cancer. The new study shows the benefits of tracking a man's PSA levels over time to help doctors more accurately assess his risk of life-threatening prostate cancer. Lead researcher Stacy Loeb, MD, is quoted.

- Stacy Loeb, MD, clinical instructor, Department of Urology

Read more: